EP Wealth Advisors LLC Takes Position in LivaNova PLC $LIVN

Key Points

• EP Wealth Advisors LLC acquired a new stake in LivaNova PLC, purchasing 7,465 shares valued at approximately $293,000 in the first quarter.
• Several institutional investors have significantly increased their holdings in LivaNova, with GAMMA Investing LLC raising its position by 2,299.7% in the first quarter.
• LivaNova's stock has been upgraded by multiple analysts, with Wolfe Research setting a price target of $60.00 and Wall Street Zen issuing a "strong-buy" rating.

EP Wealth Advisors LLC purchased a new position in LivaNova PLC (NASDAQ:LIVN - Free Report) during the 1st quarter, according to its most recent 13F filing with the SEC. The firm purchased 7,465 shares of the company's stock, valued at approximately $293,000.

Other large investors have also made changes to their positions in the company. GAMMA Investing LLC increased its stake in LivaNova by 2,299.7% during the first quarter. GAMMA Investing LLC now owns 8,759 shares of the company's stock valued at $344,000 after acquiring an additional 8,394 shares during the period. Two Sigma Advisers LP increased its position in shares of LivaNova by 148.5% during the fourth quarter. Two Sigma Advisers LP now owns 214,545 shares of the company's stock valued at $9,936,000 after purchasing an additional 128,200 shares during the period. Hsbc Holdings PLC raised its stake in shares of LivaNova by 13.4% in the first quarter. Hsbc Holdings PLC now owns 6,666 shares of the company's stock valued at $258,000 after purchasing an additional 790 shares in the last quarter. CWM LLC raised its stake in shares of LivaNova by 52.3% in the first quarter. CWM LLC now owns 871 shares of the company's stock valued at $34,000 after purchasing an additional 299 shares in the last quarter. Finally, New York State Common Retirement Fund boosted its stake in LivaNova by 28.6% during the first quarter. New York State Common Retirement Fund now owns 48,290 shares of the company's stock worth $1,897,000 after buying an additional 10,733 shares in the last quarter. Institutional investors and hedge funds own 97.64% of the company's stock.

LivaNova Price Performance

NASDAQ LIVN traded down $1.12 during trading hours on Friday, reaching $56.22. 571,347 shares of the company's stock were exchanged, compared to its average volume of 563,145. The stock has a market cap of $3.07 billion, a PE ratio of -14.45 and a beta of 0.97. LivaNova PLC has a one year low of $32.48 and a one year high of $58.91. The firm has a fifty day moving average of $49.83 and a 200-day moving average of $44.06. The company has a current ratio of 1.29, a quick ratio of 1.09 and a debt-to-equity ratio of 0.31.

LivaNova (NASDAQ:LIVN - Get Free Report) last posted its quarterly earnings data on Wednesday, August 6th. The company reported $1.05 EPS for the quarter, topping analysts' consensus estimates of $0.84 by $0.21. LivaNova had a positive return on equity of 14.57% and a negative net margin of 16.13%.The company had revenue of $352.50 million for the quarter, compared to analyst estimates of $332.20 million. During the same quarter in the previous year, the firm earned $0.93 earnings per share. The business's revenue was up 10.6% on a year-over-year basis. On average, equities research analysts predict that LivaNova PLC will post 2.85 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of equities analysts have recently issued reports on LIVN shares. Barclays increased their price objective on shares of LivaNova from $55.00 to $58.00 and gave the company an "equal weight" rating in a research note on Thursday, August 21st. Wolfe Research raised shares of LivaNova from a "peer perform" rating to an "outperform" rating and set a $60.00 price target for the company in a research report on Tuesday, May 20th. Wall Street Zen raised LivaNova from a "buy" rating to a "strong-buy" rating in a report on Saturday, August 9th. Finally, Needham & Company LLC reiterated a "buy" rating and issued a $64.00 price objective on shares of LivaNova in a research note on Wednesday, September 3rd. One research analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating and one has issued a Hold rating to the company's stock. Based on data from MarketBeat.com, LivaNova presently has a consensus rating of "Buy" and a consensus price target of $59.71.

LivaNova Company Profile

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.